The Angelman Syndrome Foundation (ASF) is a non-profit 501(c)(3) organization dedicated to advancing the understanding and treatment of [Angelman syndrome](/diseases/angelman-syndrome), a rare neurodevelopmental disorder caused by loss of function of the [UBE3A](/genes/ube3a) gene on chromosome 15. Founded in 1984, ASF serves as the primary patient advocacy organization for the Angelman community in the United States, funding research and supporting families affected by this condition.
Pathway / Mechanism Diagram
graph TD
A["UBE3A Gene (15q11.2)"] --> B["Maternal: Active in Neurons"]
A --> C["Paternal: Silenced by Imprinting"]
D["Maternal UBE3A Loss"] --> E["No Functional UBE3A"]
E --> F["Impaired Ubiquitin-Proteasome"]
F --> G["Substrate Accumulation"]
G --> H["Synaptic Dysfunction"]
H --> I["Impaired LTP"]
I --> J["Intellectual Disability"]
H --> K["E/I Imbalance"]
K --> L["Seizures"]
E --> M["Disrupted CaMKII"]
M --> N["Motor Dysfunction"]
O["Therapy: Paternal UBE3A Unsilencing"] --> P["ASO Targeting UBE3A-ATS"]
P --> Q["Restore UBE3A Expression"]
style D fill:#ef5350,color:#e0e0e0
style Q fill:#1b5e20,color:#e0e0e0
Mission
To advance the understanding and treatment of Angelman syndrome through research, advocacy, and family support. The foundation's strategic priorities include: funding innovative research, facilitating clinical trials, providing family resources, and advocating for regulatory policies that accelerate therapy development.
Key Activities
...
Overview
The Angelman Syndrome Foundation (ASF) is a non-profit 501(c)(3) organization dedicated to advancing the understanding and treatment of [Angelman syndrome](/diseases/angelman-syndrome), a rare neurodevelopmental disorder caused by loss of function of the [UBE3A](/genes/ube3a) gene on chromosome 15. Founded in 1984, ASF serves as the primary patient advocacy organization for the Angelman community in the United States, funding research and supporting families affected by this condition.
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Mission
To advance the understanding and treatment of Angelman syndrome through research, advocacy, and family support. The foundation's strategic priorities include: funding innovative research, facilitating clinical trials, providing family resources, and advocating for regulatory policies that accelerate therapy development.
Key Activities
Research Funding
ASF is a major non-governmental funder of Angelman syndrome research:
Research grants: Annual grant cycles supporting basic science, translational, and clinical research on Angelman syndrome
ASF Natural History Study: Multi-site natural history registry that has become a critical resource for clinical trial design, endpoint validation, and regulatory submissions
Biomarker consortium: Support for development of quantitative biomarkers and outcome measures for clinical trials
Therapeutic pipeline funding: Direct support for companies developing gene therapies, ASOs, and other interventions for Angelman
GeneTx Biotherapeutics Partnership
A defining partnership for ASF has been its collaboration with [GeneTx Biotherapeutics](/companies/genetx-biotherapeutics), which led to the development of GTX-102:
ASF identified UBE3A-ATS silencing as a promising therapeutic approach for Angelman syndrome
The foundation provided early research funding that enabled GeneTx to advance GTX-102 from concept to clinical trials
ASF has actively supported patient recruitment for the KIK-AS-02 (GTX-102) clinical trial
GTX-102 received FDA Breakthrough Therapy Designation and a BLA submission is expected in Q3-Q4 2026
Clinical Trial Support
The foundation facilitates clinical development through:
Patient registry: A comprehensive registry of genetically confirmed Angelman patients enabling rapid trial recruitment
Site support: Working with companies to identify and prepare clinical trial sites in the US and internationally
Natural history data: The ASF natural history study provides natural history data that can serve as external controls for single-arm trials, reducing placebo arm size
Educational webinars: Regular updates for families on clinical trial design, eligibility, and outcomes
Family Support Programs
Family resources: Educational materials, care guides, and information about available therapies and clinical trials
Family conference: Annual conference bringing together families, researchers, and industry to share knowledge and build community
Financial assistance: Emergency funds and equipment assistance for families facing financial hardship
Early intervention support: Guidance on accessing early intervention services, educational support, and therapeutic interventions
Regulatory Advocacy
ASF engages actively with regulatory agencies:
FDA engagement: Participation in FDA Patient-Focused Drug Development meetings and external input processes
Orphan drug designation: Supporting companies in obtaining orphan drug designation and rare pediatric disease priority review vouchers
Accelerated approval pathway: Advocacy for accelerated approval based on biomarker or intermediate clinical endpoints
International engagement: Collaboration with regulatory agencies in Europe and other regions
Research Priorities
ASF has identified key therapeutic targets and research priorities: